• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
CONCLUSION: This study provides strong pre-clinical and clinical evidence of the role of APAP as a potential suppressor of antitumor immunity. Hence, APAP should be used with caution in patients treated with ICB.PMID:35654248 | DOI:10.1016/j.annonc.2022.05.010
Source: Ann Oncol - June 2, 2022 Category: Cancer & Oncology Authors: A Bessede A Marabelle J P Gu égan F X Danlos S Cousin F Peyraud N Chaput M Spalato G Roubaud M Cabart M Khettab A Chaibi C Rey I Nafia F X Mahon J C Soria A Italiano Source Type: research

Top 20 Research Studies of 2020 for Primary Care Physicians
This article summarizes the top 20 research studies of 2020 identified as POEMs (patient-oriented evidence that matters), including the two most highly rated guidelines of the year on gout and chronic obstructive pulmonary disease (COPD). Regarding COVID-19, handwashing and social distancing through stay-at-home orders or quarantine measures are effective at slowing the spread of illness. Use of proper face masks (not gaiters or bandanas) is also effective at preventing trans- mission. This is important because the virus can infect others during the presymptomatic phase. Aspirin can no longer be recommended for the primary...
Source: American Family Physician - July 15, 2021 Category: Primary Care Authors: Roland Grad Mark H Ebell Source Type: research

Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails
Conclusions: Nivolumab and pembrolizumab have promising outcomes with tolerable AEs and drug-related deaths in patients with relapsed or refractory lymphoma. Pembrolizumab caused less any grade AEs like fatigue and rash than nivolumab. Patients with HL got better response than NHL. Introduction Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor mainly expressed on activated T cells, natural killer cells, and B cells (Ishida et al., 1992). The PD-L1 and PD-L2 are its known ligands, which interact with PD-1 on T cells and prevent T-cell activation and proliferation. PD-L1 is expressed on macropha...
Source: Frontiers in Pharmacology - April 30, 2019 Category: Drugs & Pharmacology Source Type: research